source
- Royalty Pharma pays $125M upfront for royalty stake in AstraZeneca’s ATTR drug cliramitugRoyalty Pharma has entered a deal to acquire a royalty interest in a transthyretin amyloidosis drug being developed by AstraZeneca. The agreement involves an upfront payment of $125 million to Neu…
- FDA sends warning letters to Sanofi and Viatris over misleading product claimsThe FDA’s Office of Prescription Drug Promotion issued untitled warning letters to Sanofi and Viatris after reviewing promotional materials that the agency deemed misleading. The letters cite spec…